• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Motor Neurone Diseases - Pipeline Review, H2 2012 Product Image

Motor Neurone Diseases - Pipeline Review, H2 2012

  • Published: October 2012
  • 271 pages
  • Global Markets Direct

Motor Neurone Diseases – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Motor Neurone Diseases - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Motor Neurone Diseases, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Motor Neurone Diseases. Motor Neurone Diseases - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Motor Neurone Diseases.
- A review of the Motor Neurone Diseases products under development by companies READ MORE >

2
List of Tables 6
List of Figures 8
Introduction 9
REPORT COVERAGE 9
Motor Neurone Diseases Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Motor Neurone Diseases 11
Motor Neurone Diseases Therapeutics under Development by Companies 13
Motor Neurone Diseases Therapeutics under Investigation by Universities/Institutes 18
Late Stage Products 21
Comparative Analysis 21
Mid Clinical Stage Products 22
Comparative Analysis 22
Early Clinical Stage Products 23
Comparative Analysis 23
Discovery and Pre-Clinical Stage Products 24
Comparative Analysis 24
Motor Neurone Diseases Therapeutics – Products under Development by Companies 25
Motor Neurone Diseases Therapeutics – Products under Investigation by Universities/Institutes 29
Companies Involved in Motor Neurone Diseases Therapeutics Development 32
Genzyme Corporation 32
Biogen Idec Inc. 33
GlaxoSmithKline plc 34
Isis Pharmaceuticals, Inc. 35
Oxford BioMedica plc 36
Amorfix Life Sciences Ltd. 37
Eisai Co., Ltd. 38
Jeil Pharmaceutical Co., Ltd. 39
Mitsubishi Tanabe Pharma Corporation 40
Sigma-Tau S.p.A. 41
Hadasit Medical Research Services & Development Ltd 42
BrainStorm Cell Therapeutics Inc. 43
Neuralstem, Inc. 44
Nutra Pharma Corporation 45
Cytokinetics, Inc 46
NeoStem, Inc. 47
Phytopharm Plc 48
Allon Therapeutics Inc. 49
MediPost Co., Ltd. 50
The Avicena Group, Inc. 51
Ceregene, Inc. 52
SCYNEXIS, Inc. 53
Snowdon Inc. 54
BioMAS Ltd. 55
Trophos SA 56
NeuroNova AB 57
Q Therapeutics, Inc. 58
ALS Therapy Development Institute 59
Reata Pharmaceuticals, Inc. 60
KineMed, Inc. 61
Omeros Corporation 62
Acetylon Pharmaceuticals, Inc. 63
Adeona Pharmaceuticals, Inc. 64
Cellceutix Corporation 65
to-BBB technologies BV 66
Maas Biolab 67
Kringle Pharma, Inc. 68
Nexgenix Pharmaceuticals, LLC 69
miRagen Therapeutics, Inc. 70
Pharnext SAS 71
Neuraltus Pharmaceuticals, Inc. 72
RhinoCyte, Inc. 73
RNL BIO Co., Ltd. 74
Varinel, Inc. 75
Motor Neurone Diseases – Therapeutics Assessment 76
Assessment by Monotherapy Products 76
Assessment by Combination Products 77
Assessment by Route of Administration 78
Assessment by Molecule Type 81
Drug Profiles 84
edaravone - Drug Profile 84
ISIS-SOD1Rx - Drug Profile 85
RTA-801 - Drug Profile 86
mecobalamin - Drug Profile 87
RPI-MN - Drug Profile 88
tirasemtiv - Drug Profile 90
dexpramipexole dihydrochloride - Drug Profile 93
CERE-135 - Drug Profile 95
AAD-2004 - Drug Profile 96
olesoxime - Drug Profile 97
MoNuDin - Drug Profile 99
AL-408 - Drug Profile 101
VAR-10300 - Drug Profile 102
ChronSeal - Drug Profile 104
noscapine - Drug Profile 106
SKL-PD - Drug Profile 107
ozanezumab - Drug Profile 108
Somatropin + Riluzole - Drug Profile 109
YAM-80 - Drug Profile 110
tauroursodeoxycholic acid - Drug Profile 111
Tretinoin + Pioglitazone - Drug Profile 112
ALS-08 + Minocycline - Drug Profile 113
NXD-30001 - Drug Profile 114
NsG-33 - Drug Profile 116
VAR-10100 - Drug Profile 118
sNN-0029 - Drug Profile 119
sodium phenylbutyrate - Drug Profile 121
ALS-08 - Drug Profile 122
memantine - Drug Profile 123
rotigotine - Drug Profile 124
pyrimethamine - Drug Profile 125
arimoclomol - Drug Profile 126
ceftriaxone - Drug Profile 127
AS-101 - Drug Profile 128
NP-001 - Drug Profile 130
smilagenin - Drug Profile 131
MTP-131 - Drug Profile 133
KM-362 - Drug Profile 135
MGN-8107 - Drug Profile 136
cyclosporine - Drug Profile 137
Autologous Mesenchymal Stem Cells Therapy - Drug Profile 139
Q-Cells - Drug Profile 140
Drug For Amyotrophic Lateral Sclerosis - Drug Profile 142
flecainide acetate - Drug Profile 143
RNAi Based Therapeutics For ALS - Drug Profile 144
AL-209 - Drug Profile 146
Ebixa + Riluzole - Drug Profile 147
Celecoxib + Creatine - Drug Profile 148
Filgrastim + Erythropoetin - Drug Profile 149
Lithium + Riluzole - Drug Profile 150
Minocycline + Creatine - Drug Profile 151
Olanzapine + Riluzole - Drug Profile 152
valproic acid - Drug Profile 153
NurOwn Stem Cell Therapy - Drug Profile 154
rasagiline - Drug Profile 156
Program For Neurological Disorders - Drug Profile 157
creatine - Drug Profile 158
tamoxifen citrate - Drug Profile 159
Memantine + Riluzole - Drug Profile 160
somatropin - Drug Profile 161
CIGB-845 - Drug Profile 162
GM-604 - Drug Profile 163
Anakinra + Riluzol - Drug Profile 164
NSI-566RSC - Drug Profile 165
Antiarrhythmic Drug - Drug Profile 167
Phosphodiesterase Type 5 Inhibitors - Drug Profile 168
Cholesterol Absorption Inhibitor - Drug Profile 169
Alpha Synuclein Program - Drug Profile 170
Tau program - Drug Profile 171
TDP-43 Programme - Drug Profile 172
NT-KO-003 - Drug Profile 173
CK-2066260 - Drug Profile 175
Drug For Amyotrophic Lateral Sclerosis - Drug Profile 176
Antibodies For Amyotrophic Lateral Sclerosis - Drug Profile 177
Vaccine For Amyotrophic Lateral Sclerosis - Drug Profile 178
HYNR-CS - Drug Profile 179
GPR139 Antagonist - Drug Profile 180
edaravone - Drug Profile 181
zinc acetate - Drug Profile 182
Drug For Amyotrophic Lateral Sclerosis - Drug Profile 183
VSEL for Motor Neurons - Drug Profile 184
KP-100IT - Drug Profile 185
2B3-201 - Drug Profile 187
TDI-167 - Drug Profile 188
TDI-176 - Drug Profile 189
TDI-172 - Drug Profile 190
TDI-163 - Drug Profile 191
TDI-173 - Drug Profile 192
TDI-34 - Drug Profile 193
TDI-170 - Drug Profile 194
TDI-119 - Drug Profile 195
TDI-133 - Drug Profile 196
fingolimod hydrochloride - Drug Profile 197
TDI-166 - Drug Profile 198
TDI-159 - Drug Profile 199
TDI-177 - Drug Profile 200
TDI-156 - Drug Profile 201
TDI-162 - Drug Profile 202
Project TDI 168 - Drug Profile 203
TDI-164 - Drug Profile 204
Project TDI 144 - Drug Profile 205
Project TDI 143 - Drug Profile 206
TDI-165 - Drug Profile 207
TDI-28 - Drug Profile 208
TDI-154 - Drug Profile 209
TDI-174 - Drug Profile 210
TDI-117 - Drug Profile 211
TDI-175 - Drug Profile 212
TDI-148 - Drug Profile 213
TDI-20 - Drug Profile 214
TDI-158 - Drug Profile 215
TDI-53 - Drug Profile 216
TDI-157 - Drug Profile 217
TDI-178 - Drug Profile 218
NT-FV-007 - Drug Profile 219
ND-602 - Drug Profile 220
ALS Therapeutic Vaccine - Drug Profile 221
CK-2127107 - Drug Profile 222
JGK-216/263 - Drug Profile 223
Cyclophilin Inhibitory Compounds - Drug Profile 224
Adipose Tissue Derived Stem Cell - Drug Profile 225
Drug for Neurofibromatosis - Drug Profile 226
Motor Neurone Diseases Therapeutics – Drug Profile Updates 227
Motor Neurone Diseases Therapeutics – Discontinued Products 247
Motor Neurone Diseases Therapeutics - Dormant Products 248
Motor Neurone Diseases – Product Development Milestones 251
Featured News & Press Releases 251
Appendix 261
Methodology 261
Coverage 261
Secondary Research 261
Primary Research 261
Expert Panel Validation 261
Contact Us 262
Disclaimer 262

List of Tables
Number of Products Under Development for Motor Neurone Diseases, H2 2012 20
Products under Development for Motor Neurone Diseases – Comparative Analysis, H2 2012 21
Number of Products under Development by Companies, H2 2012 23
Number of Products under Development by Companies, H2 2012 (Contd..1) 24
Number of Products under Development by Companies, H2 2012 (Contd..2) 25
Number of Products under Development by Companies, H2 2012 (Contd..3) 26
Number of Products under Investigation by Universities/Institutes, H2 2012 28
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 29
Comparative Analysis by Late Stage Development, H2 2012 30
Comparative Analysis by Mid Clinical Stage Development, H2 2012 31
Comparative Analysis by Early Clinical Stage Development, H2 2012 32
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 33
Products under Development by Companies, H2 2012 34
Products under Development by Companies, H2 2012 (Contd..1) 35
Products under Development by Companies, H2 2012 (Contd..2) 36
Products under Development by Companies, H2 2012 (Contd..3) 37
Products under Investigation by Universities/Institutes, H2 2012 38
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 39
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 40
Genzyme Corporation, H2 2012 41
Biogen Idec Inc., H2 2012 42
GlaxoSmithKline plc, H2 2012 43
Isis Pharmaceuticals, Inc., H2 2012 44
Oxford BioMedica plc, H2 2012 45
Amorfix Life Sciences Ltd., H2 2012 46
Eisai Co., Ltd., H2 2012 47
Jeil Pharmaceutical Co., Ltd., H2 2012 48
Mitsubishi Tanabe Pharma Corporation, H2 2012 49
Sigma-Tau S.p.A., H2 2012 50
Hadasit Medical Research Services & Development Ltd, H2 2012 51
BrainStorm Cell Therapeutics Inc., H2 2012 52
Neuralstem, Inc., H2 2012 53
Nutra Pharma Corporation, H2 2012 54
Cytokinetics, Inc, H2 2012 55
NeoStem, Inc., H2 2012 56
Phytopharm Plc, H2 2012 57
Allon Therapeutics Inc., H2 2012 58
MediPost Co., Ltd., H2 2012 59
The Avicena Group, Inc., H2 2012 60
Ceregene, Inc., H2 2012 61
SCYNEXIS, Inc., H2 2012 62
Snowdon Inc., H2 2012 63
BioMAS Ltd., H2 2012 64
Trophos SA, H2 2012 65
NeuroNova AB, H2 2012 66
Q Therapeutics, Inc., H2 2012 67
ALS Therapy Development Institute, H2 2012 68
Reata Pharmaceuticals, Inc., H2 2012 69
KineMed, Inc., H2 2012 70
Omeros Corporation, H2 2012 71
Acetylon Pharmaceuticals, Inc., H2 2012 72
Adeona Pharmaceuticals, Inc., H2 2012 73
Cellceutix Corporation, H2 2012 74
to-BBB technologies BV, H2 2012 75
Maas Biolab, H2 2012 76
Kringle Pharma, Inc., H2 2012 77
Nexgenix Pharmaceuticals, LLC, H2 2012 78
miRagen Therapeutics, Inc., H2 2012 79
Pharnext SAS, H2 2012 80
Neuraltus Pharmaceuticals, Inc., H2 2012 81
RhinoCyte, Inc., H2 2012 82
RNL BIO Co., Ltd., H2 2012 83
Varinel, Inc., H2 2012 84
Assessment by Monotherapy Products, H2 2012 85
Assessment by Combination Products, H2 2012 86
Assessment by Stage and Route of Administration, H2 2012 89
Assessment by Stage and Molecule Type, H2 2012 92
Motor Neurone Diseases Therapeutics – Drug Profile Updates 236
Motor Neurone Diseases Therapeutics – Discontinued Products 256
Motor Neurone Diseases Therapeutics – Dormant Products 257
Motor Neurone Diseases Therapeutics – Dormant Products (Contd..1) 258
Motor Neurone Diseases Therapeutics – Dormant Products (Contd..2) 259

List of Figures
Number of Products under Development for Motor Neurone Diseases, H2 2012 20
Products under Development for Motor Neurone Diseases – Comparative Analysis, H2 2012 21
Products under Development by Companies, H2 2012 22
Products under Investigation by Universities/Institutes, H2 2012 27
Late Stage Products, H2 2012 30
Mid Clinical Stage Products, H2 2012 31
Early Clinical Stage Products, H2 2012 32
Discovery and Pre-Clinical Stage Products, H2 2012 33
Assessment by Monotherapy Products, H2 2012 85
Assessment by Combination Products, H2 2012 86
Assessment by Route of Administration, H2 2012 87
Assessment by Stage and Route of Administration, H2 2012 88
Assessment by Molecule Type, H2 2012 90
Assessment by Stage and Molecule Type, H2 2012 91

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos